These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 33031539)

  • 1. Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy.
    Chow VA; Gopal AK; Gauthier J; Tseng YD; Turtle CJ; Maloney DG; Shadman M
    Blood Adv; 2020 Oct; 4(19):4869-4872. PubMed ID: 33031539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community Oncologist.
    Jacobson CA; Farooq U; Ghobadi A
    Oncologist; 2020 Jan; 25(1):e138-e146. PubMed ID: 31585984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
    Locke FL; Ghobadi A; Jacobson CA; Miklos DB; Lekakis LJ; Oluwole OO; Lin Y; Braunschweig I; Hill BT; Timmerman JM; Deol A; Reagan PM; Stiff P; Flinn IW; Farooq U; Goy A; McSweeney PA; Munoz J; Siddiqi T; Chavez JC; Herrera AF; Bartlett NL; Wiezorek JS; Navale L; Xue A; Jiang Y; Bot A; Rossi JM; Kim JJ; Go WY; Neelapu SS
    Lancet Oncol; 2019 Jan; 20(1):31-42. PubMed ID: 30518502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.
    Locke FL; Go WY; Neelapu SS
    JAMA Oncol; 2020 Feb; 6(2):281-290. PubMed ID: 31697310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
    Halford Z; Anderson MK; Bennett LL
    Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma.
    Badar T; Johnson BD; Hamadani M
    Bone Marrow Transplant; 2021 Mar; 56(3):683-685. PubMed ID: 32782349
    [No Abstract]   [Full Text] [Related]  

  • 7. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
    Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
    Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population.
    Shapiro LC; Mustafa J; Lombardo A; Khatun F; Joseph F; Gillick K; Naik A; Elkind R; Abreu M; Fehn K; de Castro A; Pradhan K; Binakaj D; Nelson R; Paroder M; Uehlinger J; Gritsman K; Alejandro Sica R; Kornblum N; Shastri A; Mantzaris I; Bachier-Rodriguez L; Verma A; Braunschweig I; Goldfinger M
    Bone Marrow Transplant; 2021 Jul; 56(7):1761-1763. PubMed ID: 33846558
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.
    Westin JR; Kersten MJ; Salles G; Abramson JS; Schuster SJ; Locke FL; Andreadis C
    Am J Hematol; 2021 Oct; 96(10):1295-1312. PubMed ID: 34310745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis.
    Abbasi A; Peeke S; Shah N; Mustafa J; Khatun F; Lombardo A; Abreu M; Elkind R; Fehn K; de Castro A; Wang Y; Derman O; Nelson R; Uehlinger J; Gritsman K; Sica RA; Kornblum N; Mantzaris I; Shastri A; Janakiram M; Goldfinger M; Verma A; Braunschweig I; Bachier-Rodriguez L
    J Hematol Oncol; 2020 Jan; 13(1):1. PubMed ID: 31900191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New European approvals: Tisagenlecleucel and Axicabtagene ciloleucel CAR-T cells - Follicular lymphoma after at least two and three prior lines of therapy].
    Cordeil S; Bachy E
    Bull Cancer; 2022 Nov; 109(11):1106-1108. PubMed ID: 36088178
    [No Abstract]   [Full Text] [Related]  

  • 12. EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma.
    Papadouli I; Mueller-Berghaus J; Beuneu C; Ali S; Hofner B; Petavy F; Tzogani K; Miermont A; Norga K; Kholmanskikh O; Leest T; Schuessler-Lenz M; Salmonson T; Gisselbrecht C; Garcia JL; Pignatti F
    Oncologist; 2020 Oct; 25(10):894-902. PubMed ID: 32339368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
    Sharma P; King GT; Shinde SS; Purev E; Jimeno A
    Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma.
    Othman T; Baird JH; Pak S; Mei M; Herrera AF; Mansour J; Shouse G; Sahebi F; Spielberger R; Cai JL; Farol L; Godfrey J; Kallam A; Phillips T; Popplewell L; Siddiqi T; Forman S; Budde LE
    Br J Haematol; 2024 Jul; 205(1):368-372. PubMed ID: 38797530
    [No Abstract]   [Full Text] [Related]  

  • 15. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
    Chow VA; Shadman M; Gopal AK
    Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The promise of CAR T-cell therapy in aggressive B-cell lymphoma.
    Nair R; Neelapu SS
    Best Pract Res Clin Haematol; 2018 Sep; 31(3):293-298. PubMed ID: 30213399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma.
    Cohen JA; Ghobadi A
    Expert Rev Anticancer Ther; 2022 Sep; 22(9):903-914. PubMed ID: 35786133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?
    Ghafouri S; Timmerman J; Larson S; Mead MD
    Bone Marrow Transplant; 2021 Apr; 56(4):974-977. PubMed ID: 33168933
    [No Abstract]   [Full Text] [Related]  

  • 19. Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement.
    Novo M; Ruff MW; Skrabek PJ; Lin Y
    Mayo Clin Proc; 2019 Nov; 94(11):2361-2364. PubMed ID: 31685159
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma.
    Bouchkouj N; Kasamon YL; de Claro RA; George B; Lin X; Lee S; Blumenthal GM; Bryan W; McKee AE; Pazdur R
    Clin Cancer Res; 2019 Mar; 25(6):1702-1708. PubMed ID: 30413526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.